India Globalization Capital’s (NYSE: IGC) Cannabis Drug Development for Alzheimer’s Backed by Previous Studies
In the U.S., more than 5.3 million people suffer from Alzheimer’s disease, and 46 million around the world have it Alzheimer’s disease cost the U.S. more than $236 billion in 2016, and the global costs topped $600 billion In 2017, IGC acquired exclusive rights to an Alzheimer’s treatment, based on THC, from the University of South Florida Huge valuation growth potential in light of other Alzheimer’s and cannabis-based companies India Globalization Capital, Inc. (NYSE MKT: IGC) has been working on phytocannabinoid-based therapies for various medical conditions for some time. Its drug development pipeline consists of treatments for seizures, neuropathic pain,…